In men , the Havrix group showed a significantly higher seroconversion rate ( 81.9 % ) than the Epaxal group ( 69.2 % ) , whereas both vaccine groups showed similarly high immunogenicity in women ( Havrix : 90.1 % , Epaxal : 92.9 % ; P for interaction = 0.062 ) .